Aquestive's Anaphylm could become the first oral epinephrine for severe allergic reactions after the FDA set a 2026 decision date without panel review.
Credo shares are trading higher Thursday after the company reported better-than-expected first quarter financial results and issued second quarter sales guidance above estimates on Wednesday after the market closed.